Top

Published in:

01-09-2021 | Care | Original Paper

Assessment of PrEP Awareness, PrEP Discussion with a Provider, and PrEP Use by Transmission Risk Group with an Emphasis on the Southern United States

Authors: Jamal T. Jones, Dawn K. Smith, Jeffrey Wiener, Euna M. August, Teresa Finlayson, Cyprian Wejnert, for the National HIV Behavioral Surveillance Study Group

Published in: AIDS and Behavior | Issue 9/2021

Abstract

The number of new HIV diagnoses is highest in the South. Many persons who might benefit from pre-exposure prophylaxis (PrEP) are not engaged in the HIV PrEP continuum of care. We analyzed National HIV Behavioral Surveillance data to assess engagement in the PrEP continuum of care among persons with increased HIV risk. We compared PrEP awareness, discussion with a clinical provider, and use among persons living in the South to those living elsewhere in the United States. PrEP awareness was lowest among heterosexual persons (7%), highest among men who have sex with men (85%), and 26% among persons who inject drugs. PrEP use was low among each population (≤ 35% for all cycles). There was limited evidence of differences in PrEP use between persons in southern and non-southern U.S. Efforts are needed to increase use of PrEP among each of the groups with increased HIV risk.

Available only for authorised users

United States Census Bureau. 2019. https://www.census.gov/popclock/data_tables.php?component=growth. Accessed 23 Oct 2019.

Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas. 2017. HIV Surveill Rep 2018;29. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2017-vol-29.pdf. Accessed 12 Aug 2019.

Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67(41):1147–50.CrossRefPubMedPubMedCentral

Thigpen MC, Kebaabetswe PM, Paxton LA, TDF2 Study Group, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed

Baeten JM, Donnell D, Ndase P, Partners PrEP Study Team, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral

Choopanya K, Martin M, Suntharasamai P, Bangkok Tenofovir Study Group, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed

Grant RM, Lama JR, Anderson PL, iPrEx Study Team, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral

Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28:833–40.CrossRefPubMedPubMedCentral

Smith DK, Chang MH, Duffus WA, Okoye S, Weissman S. Missed opportunities to prescribe preexposure prophylaxis in South Carolina, 2013–2016. Clin Infect Dis. 2019;68(1):37–42.CrossRefPubMed

10.

Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, et al. Defining the HIV pre-exposure prophylaxis care continuum. AIDS. 2017;31(5):731–4.CrossRefPubMed

11.

Kelley CF, Kahle E, Siegler A, et al. Applying a PrEP continuum of care for men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2015;61(10):1590–7.CrossRefPubMedPubMedCentral

12.

Iqbal K, Zhu W, Dominguez KL, Tanner M, Henny KD, Hoover KW. PrEP continuum of care among MSM and TGW of color in the THRIVE demonstration project. Poster presented at: CROI 2020; Mar 8–11, 2020; Boston, MA.

13.

Walters SM, Rivera AV, Starbuck L, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011–2013. J Acquir Immune Defic Syndr. 2017;75(Suppl 3):S383–91.CrossRefPubMed

14.

Raifman JR, Schwartz SR, Sosnowy CD, Montgomery MC, Almonte A, Bazzi AR, Drainoni ML, Stein MD, Willie TC, Nunn AS, Chan PA. Brief report: pre-exposure prophylaxis awareness and use among cisgender women at a sexually transmitted disease clinic. J Acquir Immune Defic Syndr. 2019;80(1):36–9.CrossRefPubMedPubMedCentral

15.

Finlayson T, Cha S, Xia M, et al. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men—20 urban areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019;68(27):597–603. https://doi.org/10.15585/mmwr.mm6827a1.CrossRefPubMedPubMedCentral

16.

Kanny D, Jeffries WL 4th, Chapin-Bardales J, National HIV Behavioral Surveillance Study Group, et al. Racial/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men—23 urban areas, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(37):801–6. https://doi.org/10.15585/mmwr.mm6837a2.CrossRefPubMedPubMedCentral

17.

Roth A, Tran N, Piecara B, Welles S, Shinefeld J, Brady K. Factors associated with awareness of pre-exposure prophylaxis for HIV among persons who inject drugs in Philadelphia: National HIV Behavioral Surveillance, 2015. AIDS Behav. 2019;23(7):1833–40.CrossRefPubMed

18.

McFarland W, Lin J, Santos GM, Arayasirikul S, Raymond HF, Wilson E. Low PrEP awareness and use among people who inject drugs, San Francisco, 2018. AIDS Behav. 2020;24(5):1290–3. https://doi.org/10.1007/s10461-019-02682-7.CrossRefPubMed

19.

Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.CrossRefPubMedPubMedCentral

20.

Centers for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among heterosexuals at increased risk of HIV infection—National HIV Behavioral Surveillance, 17 U.S. Cities, 2016. HIV Surveill Spec Rep. 19. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 23 Oct 2019.

21.

Wejnert C, Xia M, Doyle K, Paz-Bailey G, NHBS Study Group. HIV infection risk, prevention, and testing behaviors among men who have sex with men national HIV behavioral surveillance—20 U.S. cities, 2014. HIV Surveill Rep Spec Rep. 2016;15:1–32.

22.

Wejnert C, Hess KL, Hall HI, Van Handel M, Hayes D, Fulton P Jr. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs—United States. MMWR Morb Mortal Wkly Rep. 2016;65(47):1336–42.CrossRefPubMed

23.

MacKellar DA, Gallagher KM, Finlayson T, Sanchez T, Lansky A, Sullivan PS. Surveillance of HIV risk and prevention behaviors of men who have sex with men—a national application of venue-based, time-space sampling. Public Health Rep. 2007;122(suppl 1):39–47.CrossRefPubMedPubMedCentral

24.

Lansky A, Abdul-Quader AS, Cribbin M, et al. Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122(suppl 1):48–55.CrossRefPubMedPubMedCentral

25.

Patel RR, Mena L, Nunn A, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE. 2017;12(5):e0178737. https://doi.org/10.1371/journal.pone.0178737.CrossRefPubMedPubMedCentral

26.

Weiser J, Garg S, Beer L, Skarbinski J. Prescribing of human immunodeficiency virus (HIV) pre-exposure prophylaxis by HIV medical providers in the United States, 2013–2014. Open Forum Infect Dis. 2017;4(1):ofx003.CrossRefPubMedPubMedCentral

27.

Biello KB, Bazzi AR, Mimiaga MJ. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55. https://doi.org/10.1186/s12954-018-0263-5.CrossRefPubMedPubMedCentral

28.

Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.CrossRefPubMedPubMedCentral

29.

Jones JT, deCastro BR, August EM, Smith DK. Pre-exposure prophylaxis (PrEP) awareness and prescribing behaviors among primary care providers: DocStyles survey, 2016–2020, United States. AIDS Behav. 2020. https://doi.org/10.1007/s10461-020-03089-5.CrossRefPubMedPubMedCentral

30.

Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28:841–9.CrossRefPubMedPubMedCentral

31.

Huang YA, Tao G, Smith DK, Hoover KW. Persistence with human immunodeficiency virus pre-exposure prophylaxis in the United States, 2012–2017. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa037.CrossRefPubMedPubMedCentral

Title: Assessment of PrEP Awareness, PrEP Discussion with a Provider, and PrEP Use by Transmission Risk Group with an Emphasis on the Southern United States
Authors: Jamal T. Jones
Dawn K. Smith
Jeffrey Wiener
Euna M. August
Teresa Finlayson
Cyprian Wejnert
for the National HIV Behavioral Surveillance Study Group
Publication date: 01-09-2021
Publisher: Springer US
Keywords: Care
Human Immunodeficiency Virus
Published in: AIDS and Behavior / Issue 9/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-021-03164-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Assessment of PrEP Awareness, PrEP Discussion with a Provider, and PrEP Use by Transmission Risk Group with an Emphasis on the Southern United States

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2021

The Impact of COVID-19 on HIV Self-Management, Affective Symptoms, and Stress in People Living with HIV in the United States

A Systematic Review of the Social Network Strategy to Optimize HIV Testing in Key Populations to End the Epidemic in the United States

Understanding Reasons for HIV Late Diagnosis: A Qualitative Study Among HIV-Positive Individuals in Amsterdam, The Netherlands

Psychosocial Mechanisms of Self-rated Successful Aging with HIV: A Structural Equation Model

Long-term Patterns of Self-reported Opioid Use, VACS Index, and Mortality Among People with HIV Engaged in Care

South African Fathers Involvement and Their Adolescents’ Sexual Risk Behavior and Alcohol Consumption

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page